Pediatric Head and Neck Rhabdomyosarcoma

Carol J. Macarthur; Trevor J.I. Mcgill; Gerald B. Healy

doi:10.1177/000992289203100201

Pediatric Head and Neck Rhabdomyosarcoma

Carol J. Macarthur, Trevor J.I. Mcgill, Gerald B. Healy

Otolaryngology

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Rhabdomyosarcoma (RMS), the most common malignant soft-tissue tumor in the pediatric population, occurs most often in the head and neck region. Major advancements in the management of these aggressive tumors have been achieved in the last 20 years on three fronts: chemotherapy, radiation therapy, and surgery. Surgery, with the advent of skull-base, craniofacial, and free-tissue-transfer reconstructive techniques, has once again become part of the primary management of these tumors. Prior to 1960, RMS was uniformly fatal; now, with the introduction of multimodality treatment regimens, two thirds of patients can expect long-term survival.

Original language	English (US)
Pages (from-to)	66-70
Number of pages	5
Journal	Clinical pediatrics
Volume	31
Issue number	2
DOIs	https://doi.org/10.1177/000992289203100201
State	Published - Feb 1992

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1177/000992289203100201

Fingerprint Dive into the research topics of 'Pediatric Head and Neck Rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this

@article{835205e0ee5145ef881c487cc517176e,

title = "Pediatric Head and Neck Rhabdomyosarcoma",

abstract = "Rhabdomyosarcoma (RMS), the most common malignant soft-tissue tumor in the pediatric population, occurs most often in the head and neck region. Major advancements in the management of these aggressive tumors have been achieved in the last 20 years on three fronts: chemotherapy, radiation therapy, and surgery. Surgery, with the advent of skull-base, craniofacial, and free-tissue-transfer reconstructive techniques, has once again become part of the primary management of these tumors. Prior to 1960, RMS was uniformly fatal; now, with the introduction of multimodality treatment regimens, two thirds of patients can expect long-term survival.",

author = "Macarthur, {Carol J.} and Mcgill, {Trevor J.I.} and Healy, {Gerald B.}",

year = "1992",

month = feb,

doi = "10.1177/000992289203100201",

language = "English (US)",

volume = "31",

pages = "66--70",

journal = "Clinical Pediatrics",

issn = "0009-9228",

publisher = "SAGE Publications Inc.",

number = "2",

}

TY - JOUR

T1 - Pediatric Head and Neck Rhabdomyosarcoma

AU - Macarthur, Carol J.

AU - Mcgill, Trevor J.I.

AU - Healy, Gerald B.

PY - 1992/2

Y1 - 1992/2

N2 - Rhabdomyosarcoma (RMS), the most common malignant soft-tissue tumor in the pediatric population, occurs most often in the head and neck region. Major advancements in the management of these aggressive tumors have been achieved in the last 20 years on three fronts: chemotherapy, radiation therapy, and surgery. Surgery, with the advent of skull-base, craniofacial, and free-tissue-transfer reconstructive techniques, has once again become part of the primary management of these tumors. Prior to 1960, RMS was uniformly fatal; now, with the introduction of multimodality treatment regimens, two thirds of patients can expect long-term survival.

AB - Rhabdomyosarcoma (RMS), the most common malignant soft-tissue tumor in the pediatric population, occurs most often in the head and neck region. Major advancements in the management of these aggressive tumors have been achieved in the last 20 years on three fronts: chemotherapy, radiation therapy, and surgery. Surgery, with the advent of skull-base, craniofacial, and free-tissue-transfer reconstructive techniques, has once again become part of the primary management of these tumors. Prior to 1960, RMS was uniformly fatal; now, with the introduction of multimodality treatment regimens, two thirds of patients can expect long-term survival.

UR - http://www.scopus.com/inward/record.url?scp=0026684694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026684694&partnerID=8YFLogxK

U2 - 10.1177/000992289203100201

DO - 10.1177/000992289203100201

M3 - Article

C2 - 1544277

AN - SCOPUS:0026684694

VL - 31

SP - 66

EP - 70

JO - Clinical Pediatrics

JF - Clinical Pediatrics

SN - 0009-9228

IS - 2

ER -